z-logo
open-access-imgOpen Access
miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers
Author(s) -
Anne-Marie Givel,
Yann Kieffer,
Alix Scholer-Dahirel,
Philémon Sirven,
Mélissa Cardon,
Floriane Pelon,
Ilaria Magagna,
Géraldine Gentric,
Ana Costa,
Claire Bonneau,
Virginie Mieulet,
Anne VincentSalomon,
Fatima MechtaGrigoriou
Publication year - 2018
Publication title -
nature communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.559
H-Index - 365
ISSN - 2041-1723
DOI - 10.1038/s41467-018-03348-z
Subject(s) - mesenchymal stem cell , stromal cell , cancer research , ovarian carcinoma , immunosuppression , foxp3 , biology , stroma , chemokine , cancer , ovarian cancer , immunology , microbiology and biotechnology , immunohistochemistry , immune system , genetics
High-grade serous ovarian cancers (HGSOC) have been subdivided into molecular subtypes. The mesenchymal HGSOC subgroup, defined by stromal-related gene signatures, is invariably associated with poor patient survival. We demonstrate that stroma exerts a key function in mesenchymal HGSOC. We highlight stromal heterogeneity in HGSOC by identifying four subsets of carcinoma-associated fibroblasts (CAF-S1-4). Mesenchymal HGSOC show high content in CAF-S1 fibroblasts, which exhibit immunosuppressive functions by increasing attraction, survival, and differentiation of CD25 + FOXP3 + T lymphocytes. The beta isoform of the CXCL12 chemokine (CXCL12β) specifically accumulates in the immunosuppressive CAF-S1 subset through a miR-141/200a dependent-mechanism. Moreover, CXCL12β expression in CAF-S1 cells plays a crucial role in CAF-S1 immunosuppressive activity and is a reliable prognosis factor in HGSOC, in contrast to CXCL12α. Thus, our data highlight the differential regulation of the CXCL12α and CXCL12β isoforms in HGSOC, and reveal a CXCL12β-associated stromal heterogeneity and immunosuppressive environment in mesenchymal HGSOC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here